<DOC>
	<DOC>NCT01331109</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.</brief_summary>
	<brief_title>Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Patients must have completed or discontinued prematurely from leadin study, MLNMD14, tolerating a minimum daily dose of 50mg milnacipran Can not tolerate a minimum daily dose of 50mg milnacipran Significant risk of suicidality Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Pediatric Fibromyalgia</keyword>
	<keyword>Adolescent Fibromyalgia</keyword>
	<keyword>milnacipran</keyword>
	<keyword>Savella</keyword>
	<keyword>loss of therapeutic response</keyword>
	<keyword>Forest Research Institute</keyword>
	<keyword>Pain</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Serotonin Norepinephrine Reuptake Inhibitors</keyword>
</DOC>